Does telmisartan have a labelled dose while on cycle?

Tablet strengths and forms
SourceStrengthsPacks
US label20 mg, 40 mg and 80 mg tabletsBottles of 30 and 1000 tablets for each strength1
EU product information40 mg and 80 mg tablets; the 20 mg tablet is not marketedBlisters of 14, 28, 56, 84 or 98 tablets, unit dose blisters and multipacks of 360; not all sizes may be marketed2

The US label gives a starting dose of 40 mg once daily and a range of 40 to 80 mg once daily for hypertension, and the EU product information a maximum of 80 mg once daily for essential hypertension, while searches of DailyMed, ClinicalTrials.gov and PubMed returned no label or human trial of telmisartan during an anabolic steroid or performance cycle.12

Tablet strengths and forms

The table is set at the top of the page

Both texts describe a tablet for oral use, and neither gives an injection route.12

Dose and timing on the label

For essential hypertension, the EU product information gives a usually effective dose of 40 mg once daily.2

The EU product information says the dose can be increased to a maximum of 80 mg once daily where the target blood pressure is not achieved, so a day's dose of two 80 mg tablets sits above it.2 The Wohl 2010 crossover gave 160 mg a day, while the Hsueh 2010 trial gave 80 mg a day for 2 weeks and the Chetty 2014 trial 80 mg a day for 4 weeks before each raised the dose to 160 mg, all in selected trial groups; 160 mg a day is not a label dose.345

Trial doses

TrialDose and schedulePeopleLength
ONTARGET (Yusuf 2008), people with vascular disease or high-risk diabetes80 mg per day, against ramipril 10 mg per day and both drugs8542 on telmisartan, 8576 on ramipril, 8502 on bothMedian follow-up of 56 months6
TRANSCEND (Yusuf 2008), people intolerant to ACE inhibitors with cardiovascular disease or diabetes with end-organ damage80 mg per day or placebo5926 people, 2954 on telmisartan, 2972 on placeboMedian 56 months7
Fogari 2009 crossover, overweight outpatients with mild to moderate hypertension80 mg or eprosartan 600 mg, each after a 4-week placebo periodFifty outpatients8 weeks each period8
Wohl 2010 double-blind crossover, patients with metabolic syndrome and impaired fasting glucose160 mg per day or placeboTwelve patients completed3 weeks each, with a 2-week washout3
Hsueh 2010 phase 2 trial, overweight or obese adults without diabetes or hypertension80 mg per day for 2 weeks, then 160 mg for 14 weeks, or placebo138 randomised, 128 completed16 weeks4
Chetty 2014 trial, adults with abdominal obesity80 mg per day for 4 weeks, then 160 mg, or placeboNinety-five adults24 weeks5

In the Fogari crossover in overweight outpatients with mild to moderate hypertension, insulin sensitivity (glucose infusion rate) rose by 2.25 micromol/min/kg with telmisartan (p<0.05 against placebo) and by 0.25 micromol/min/kg with eprosartan, which was not significant.8 In the Chetty trial, telmisartan had no significant effect on soleus muscle fat or liver fat in people on either a low or high glycemic diet, and body composition, lipids, glucose, insulin sensitivity and adiponectin were unaffected, while beta-cell function improved (p = 0.03; a 16.5% increase from baseline in the telmisartan group).5

Telmisartan during a cycle

Searches of DailyMed, ClinicalTrials.gov and PubMed returned no label or human trial of telmisartan during an anabolic steroid or performance cycle. The Hsueh trial excluded people on steroids or glucocorticoids, so it says nothing about telmisartan alongside them.4 A search of the saved WADA Prohibited List for "telmisartan" and "angiotensin" returned no passage, so no claim about its anti-doping status is made.

Safety warnings

The US label carries a boxed warning on fetal toxicity.1 It warns that symptomatic hypotension may occur after starting telmisartan in volume- or salt-depleted patients, such as those on high doses of diuretics, and that hyperkalemia may occur, particularly with advanced renal impairment, heart failure, renal replacement therapy, potassium supplements, potassium-sparing diuretics, potassium-containing salt substitutes or other drugs that increase potassium levels.1 The EU product information says other blood-pressure medicines can increase the blood pressure effect.2

Storage

The US label gives room-temperature storage of 20° to 25°C, with excursions of 15° to 30°C permitted, and says tablets stay in the bottle until just before use.1

Frequently asked questions

What is the dosing in liver or kidney impairment?

The EU product information gives a limit of 40 mg once daily in mild to moderate hepatic impairment and no posology adjustment in mild to moderate renal impairment; for severe renal impairment or haemodialysis it notes limited experience and gives a lower starting dose of 20 mg, though the 20 mg Micardis tablet is not marketed; severe hepatic impairment is a contraindication.2 The US label says no initial dosage adjustment is necessary in renal impairment, including on hemodialysis, while noting that patients on dialysis may develop orthostatic hypotension and need close blood pressure monitoring.1

References

  1. DailyMed (Alembic). These highlights do not include all the information needed to use TELMISARTAN TABLETS safely and effectively. See full prescribing information for TELMISARTAN TABLETS. TELMISARTAN tablets, for oral use Initial U.S. Approval: 1998. 2026. dailymed.nlm.nih.gov
  2. EMA. Micardis, INN-telmisartan. ema.europa.eu
  3. PubMed. Effect of telmisartan on selected adipokines, insulin sensitivity, and substrate utilization during insulin-stimulated conditions in patients with metabolic syndrome and impaired fasting glucose. 2010. pubmed.ncbi.nlm.nih.gov
  4. PMC. Telmisartan Effects on Insulin Resistance in Obese or Overweight Adults Without Diabetes or Hypertension. pmc.ncbi.nlm.nih.gov
  5. PubMed. Metabolic effects of telmisartan in subjects with abdominal obesity: a prospective randomized controlled trial. 2014. pubmed.ncbi.nlm.nih.gov
  6. PubMed. Telmisartan, ramipril, or both in patients at high risk for vascular events. 2008. pubmed.ncbi.nlm.nih.gov
  7. PubMed. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. 2008. pubmed.ncbi.nlm.nih.gov
  8. PubMed. Comparative effects of telmisartan and eprosartan on insulin sensitivity in the treatment of overweight hypertensive patients. 2009. pubmed.ncbi.nlm.nih.gov